Aidoc
Always-on clinical AI that triages CT findings — ICH, PE, spinal fractures and 30+ more — across nearly 2,000 hospitals.
Overview
Aidoc is a Tel Aviv-founded clinical AI company whose aiOS enterprise platform continuously monitors CT and X-ray studies for more than 30 FDA-cleared acute findings, including intracranial hemorrhage, pulmonary embolism, cervical spine fractures, large-vessel occlusions, and — since January 2026 — 14 abdominal CT indications detected simultaneously by its CARE foundation model. The platform integrates directly with PACS, VNA, EHR (including Epic via App Orchard), and worklists, surfacing prioritised alerts to radiologists and care teams without requiring workflow disruption. It is deployed across nearly 2,000 hospitals globally and has analysed more than 110 million cumulative patient cases.
Founded in 2016 by three Israeli Defence Forces Talpiot programme alumni, Aidoc has raised over $520 million in total funding — including a $150 million Series E in April 2026 led by Goldman Sachs Alternatives, with SoftBank Vision Fund 2, General Catalyst, and NVIDIA's NVentures participating. The company targets an order-of-magnitude reduction in false alerts compared with single-condition tools, and is expanding CARE to cover all CT and X-ray workflows within 18 months, with automated draft radiology reports on the roadmap.
Pricing
Pricing shown for reference only. These figures reflect RECATOOLS research as of 16 Jun 2026 and may be out of date or incomplete. This is not financial or purchasing advice — always confirm the current price on the provider’s official website before making any decision.
Use cases
What you can produce with Aidoc
- FDA-cleared real-time triage for ~30 FDA-cleared triage algorithms (primarily CT, with X-ray indications expanding) delivered to the radiologist worklist
- Unified aiOS dashboard consolidating Aidoc and third-party AI alerts with urgency-based prioritisation
- Epic integration (via Epic's app marketplace / Showroom) providing acuity-based worklist reordering directly inside Radiant
- CARE foundation model report covering 14 simultaneous abdominal CT indications from a single AI inference pass
- Care-team notifications (mobile, pager, EHR) routing critical findings to treating clinicians before final radiology read
- Continuous performance monitoring and governance reporting for clinical AI deployed across a health system
- Implementation and onboarding support with typical go-live in two to three weeks
ASEAN Perspective
Aidoc in Southeast Asia
Aidoc's APAC presence is currently concentrated in Australia and New Zealand through its Integral Diagnostics partnership (600,000+ cases since 2019), with the company's own materials noting broader "Asia" deployments without naming specific ASEAN facilities. Southeast Asian public hospitals — which handle heavy emergency CT volumes in countries such as Indonesia, Vietnam, and the Philippines — could benefit from acute-triage AI, but Aidoc's enterprise pricing model and US/EU regulatory focus (FDA and CE marks rather than local equivalents like Singapore HSA or Malaysia MDA) limit near-term accessibility. ASEAN private hospital groups and teleradiology networks are more likely early adopters, contingent on Aidoc prioritising regional regulatory submissions and local-language support.
Aidoc leads the FDA-cleared radiology AI market by clearance count and clinical breadth. Its CARE foundation model — the first to receive FDA clearance for 14 simultaneous abdominal CT indications — represents a genuine leap beyond single-condition triage tools, and the aiOS platform's vendor-agnostic integration (PACS, VNA, Epic, FHIR/HL7) makes deployment tractable for large health systems. Sensitivity and specificity figures published in the CARE pivotal study (97–99.7% across indications) are credible, peer-reviewed numbers, not marketing claims.
The main caveats are accessibility and scope. Aidoc is an enterprise-only product with opaque custom pricing that effectively excludes smaller radiology practices and most ASEAN public-sector facilities without procurement capacity. Geographic footprint in Southeast Asia is thin — confirmed deployments are in Australia/New Zealand (Integral Diagnostics) with only generalised "Asia" mentions elsewhere. The platform is focused on acute emergency imaging; it does not address longitudinal disease management, pathology, or non-CT modalities at scale. Alert fatigue from parallel AI tools remains an industry-wide concern that aiOS partly mitigates through consolidation, but individual institution results vary.
What people say
Aidoc is one of the most widely deployed clinical-AI triage platforms in radiology and a leader in FDA-cleared real-time triage, with roughly 30 cleared algorithms. Its CARE foundation model consolidates multi-condition abdominal-CT triage into a single inference pass, a clinically and operationally meaningful advance. Independent studies support high sensitivity and specificity for core indications, and deep Epic integration plus vendor-agnostic PACS connectivity reduce friction for large US health systems. Limitations: enterprise-only opaque pricing, limited ASEAN footprint beyond Australia/NZ, and a focus on acute emergency CT that excludes screening and longitudinal use. Crowdsourced reviews are sparse, so ratings lean on published clinical evidence and market traction.
Summary of public user & expert reviews, compiled by RECATOOLS.
Notable facts
- All three co-founders are graduates of the IDF's elite Talpiot technology programme, which selects fewer than 30 candidates per year.
- Aidoc's CARE foundation model was the first AI system to receive FDA clearance for detecting 14 different acute CT findings using a single unified model, announced January 2026.
- Aidoc is the only AI vendor integrated directly into Epic's Radiant worklist via the App Orchard, meaning radiologists get AI flags without leaving their existing workflow.
- NVIDIA's venture arm NVentures joined both the 2025 growth round and the 2026 Series E, signalling alignment with NVIDIA's medical imaging GPU infrastructure strategy.
Frequently asked questions
About this listing
This entry was compiled from publicly available data including Aidoc's official website, press releases, documentation, and reputable third-party publications. RECATOOLS is not affiliated with Aidoc unless explicitly stated.
Third-party AI tools update their pricing, features, availability, and policies frequently. Information here may be outdated by the time you read this — we make reasonable efforts to keep listings current, but cannot guarantee absolute accuracy.
For the latest details, please refer to Aidoc directly →
Spotted something out of date? Suggest an update →
More in Other
